BSE Live
Oct 29, 10:31Prev. Close
1283.85
Open Price
1284.70
Bid Price (Qty.)
1283.05 (7)
Offer Price (Qty.)
1284.90 (5)
NSE Live
Oct 29, 10:31Prev. Close
1285.90
Open Price
1292.30
Bid Price (Qty.)
1283.20 (8)
Offer Price (Qty.)
1284.40 (1)
| Key Financial Ratios of Ipca Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 36.75 | 26.16 | 19.93 | 34.33 | 90.08 | |
| Diluted EPS (Rs.) | 25.65 | 20.91 | 19.93 | 34.33 | 90.08 | |
| Cash EPS (Rs.) | 35.58 | 30.62 | 28.94 | 42.37 | 104.73 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 271.64 | 250.24 | 231.66 | 217.71 | 374.67 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 271.64 | 250.24 | 231.66 | 217.71 | 374.67 | |
| Dividend / Share(Rs.) | 4.00 | 4.00 | 4.00 | 4.00 | 8.00 | |
| Revenue from Operations/Share (Rs.) | 263.22 | 243.06 | 229.19 | 212.82 | 405.14 | |
| PBDIT/Share (Rs.) | 62.92 | 52.14 | 40.32 | 51.23 | 124.23 | |
| PBIT/Share (Rs.) | 52.99 | 42.42 | 31.31 | 43.18 | 109.43 | |
| PBT/Share (Rs.) | 39.41 | 32.41 | 29.58 | 42.90 | 108.79 | |
| Net Profit/Share (Rs.) | 25.65 | 20.91 | 19.93 | 34.33 | 89.93 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 23.90 | 21.44 | 17.59 | 24.07 | 30.66 | |
| PBIT Margin (%) | 20.13 | 17.45 | 13.66 | 20.29 | 27.01 | |
| PBT Margin (%) | 14.97 | 13.33 | 12.90 | 20.15 | 26.85 | |
| Net Profit Margin (%) | 9.74 | 8.60 | 8.69 | 16.13 | 22.19 | |
| Return on Networth / Equity (%) | 9.44 | 8.35 | 8.60 | 15.76 | 24.00 | |
| Return on Capital Employed (%) | 17.57 | 15.07 | 11.73 | 17.87 | 28.07 | |
| Return on Assets (%) | 7.17 | 6.12 | 5.98 | 11.66 | 18.98 | |
| Total Debt/Equity (X) | 0.13 | 0.18 | 0.24 | 0.14 | 0.05 | |
| Asset Turnover Ratio (%) | 0.75 | 0.72 | 0.73 | 0.80 | 0.92 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.69 | 2.31 | 2.91 | 3.13 | 3.08 | |
| Quick Ratio (X) | 1.60 | 1.21 | 1.92 | 1.82 | 1.65 | |
| Inventory Turnover Ratio (X) | 4.15 | 1.01 | 0.99 | 0.98 | 1.12 | |
| Dividend Payout Ratio (NP) (%) | 15.59 | 9.56 | 20.06 | 11.65 | 8.89 | |
| Dividend Payout Ratio (CP) (%) | 11.24 | 6.53 | 13.81 | 9.43 | 7.63 | |
| Earnings Retention Ratio (%) | 84.41 | 90.44 | 79.94 | 88.35 | 91.11 | |
| Cash Earnings Retention Ratio (%) | 88.76 | 93.47 | 86.19 | 90.57 | 92.37 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 38,795.18 | 32,434.39 | 20,273.86 | 27,089.42 | 24,053.30 | |
| EV/Net Operating Revenue (X) | 5.81 | 5.26 | 3.49 | 5.02 | 4.68 | |
| EV/EBITDA (X) | 24.30 | 24.52 | 19.82 | 20.84 | 15.26 | |
| MarketCap/Net Operating Revenue (X) | 5.70 | 5.09 | 3.54 | 4.99 | 4.70 | |
| Retention Ratios (%) | 84.40 | 90.43 | 79.93 | 88.34 | 91.10 | |
| Price/BV (X) | 5.53 | 4.95 | 3.50 | 4.87 | 5.08 | |
| Price/Net Operating Revenue | 5.70 | 5.09 | 3.54 | 4.99 | 4.70 | |
| Earnings Yield | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 |
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
13.08.2025
Accumulate Ipca Laboratories; target of Rs 1525: Prabhudas Lilladher
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
03.06.2025
Ipca Labs Consolidated March 2025 Net Sales at Rs 2,246.69 crore, up 10.51% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
03.06.2025
Ipca Labs Consolidated March 2025 Net Sales at Rs 2,246.69 crore, up 10.51% Y-o-Y
04.03.2025
Ipca Labs Consolidated December 2024 Net Sales at Rs 2,245.37 crore, up 9.38% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher